Drugs / BMS-863233
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00886782 | May 2009 → Aug 2010 | metastatic malignant neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00838890 Comparator | Mar 2009 → Jan 2010 | refractory hematologic cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-863233 | “BMS-863233” NCT00886782 ↗ |
| Known as | XL-413 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544944 ↗ |
| Action | Inhibit | “Cdc7-inhibitor (BMS-863233)” NCT00838890 ↗ |
| Modality | Small molecule | — CHEMBL3544944 ↗ |
| Route | Oral | “Tablets, Oral” NCT00838890 ↗ |
| Target | CDC7 | “Cdc7-inhibitor (BMS-863233)” NCT00838890 ↗ |